Altered serum levels of TNF-α, IL-6 and IL-18 in manic, depressive, mixed state of bipolar disorder patients

Psychiatry Research

Volumn 244, Issue , 2016, Pages 19-23

  Luo, Yayan ^a   He, Hongbo ^a   Zhang, Minling ^a   Huang, Xini ^a   Fan, Ni ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Bipolar disorder; Cytokines; IL 18; IL 6; TNF

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER; CYTOKINE; IL6 PROTEIN, HUMAN; INTERLEUKIN 18; INTERLEUKIN 18 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ADULT; AGE; ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; CORRELATIONAL STUDY; DEMOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHOSIS; SEX DIFFERENCE; ADOLESCENT; BLOOD; DEPRESSION; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; SMOKING; YOUNG ADULT;

ADOLESCENT; ADULT; BIOMARKERS; BIPOLAR DISORDER; CYTOKINES; DEPRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-18; INTERLEUKIN-6; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SMOKING; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84978818198     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2016.07.027     Document Type: Article

References (44)

1. Alboni, S., Cervia, D., Sugama, S., Conti, B., Interleukin 18 in the CNS. J. Neuroinflamm., 7, 2010, 9.
2. Alcocer-Gómez, E., de Miguel, M., Casas-Barquero, N., Núñez-Vasco, J., Sánchez-Alcazar, J.A., Fernández-Rodríguez, A., et al. NLRP3 inflammasome is activated in mononuclear blood cells from patients with major depressive disorder. Brain Behav. Immun. 36 (2014), 111–117.
3. Al-Hakeim, H.K., Al-Rammahi, D.A., Al-Dujaili, A.H., IL-6, IL-18, sIL-2R, and TNFα proinflammatory markers in depression and schizophrenia patients who are free of overt inflammation. J. Affect. Disord. 82 (2015), 106–114.
4. Bai, Y.M., Su, T.P., Tsai, S.T., Wen-Fei, C., Li, C.T., Pei-Chi, T., Mu-Hong, C., Comparison of inflammatory cytokine levels among type I/type II and manic/hypomanic/euthymic/depressive states of bipolar disorder. J. Affect. Disord. 166 (2014), 187–192.
5. Barbosa, I.G., Bauer, M.E., Machado-Vieira, R., Teixeira, A.L., Cytokines in bipolar disorder: paving the way for neuroprogression. Neural Plast. 360481 (2014), 1–9.
6. Berk, M., Kapczinski, F., Andreazza, A.C., Dean, O.M., Giorlando, F., Maes, M., et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci. Biobehav. Rev. 35 (2011), 804–817.
7. Berk, M., Neuroprogression: pathways to progressive brain changes in bipolar disorder. Int. J. Neuropsychopharmacol. 12:4 (2009), 41–445.
8. Brietzke, E., Stertz, L., Fernandes, B.S., Kauer-Sant'anna, M., Mascarenhas, M., Escosteguy Vargas, A., et al. Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. J. Affect. Disord. 116 (2009), 214–217.
9. Brietzke, E., Kapczinski, F., TNF-alpha as a molecular target in bipolar disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 32 (2008), 1355–1361.
10. Cohen, J., A power primer. Psychol. Bull. 112 (1992), 155–159.
11. Cunha, A.B., Andreazza, A.C., Gomes, F.A., Frey, B.N., da Silveira, L.E., Gonçalves, C.A., et al. Investigation of serum high-sensitive C-reactive protein levels across all mood states in bipolar disorder. Eur. Arch. Psychiatry Clin. Neurosci. 258 (2008), 300–304.
12. Dickerson, F., Stallings, C., Origoni, A., Boronow, J., Yolken, R., Elevated serum levels of C-reactive protein are associated with mania symptoms in out-patients with bipolar disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 31 (2007), 952–955.
13. Drexhage, R.C., van der Heul-Nieuwenhuijsen, L., Padmos, R.C., van Beveren, N., Cohen, D., Versnel, M.A., et al. Inflammatory gene expression in monocytes of patients with schizophrenia: overlap and difference with bipolar disorder. A study in naturalistically treated patients. Int. J. Neuropsychopharmacol. 13 (2010), 1369–1381.
14. Felderhoff-Mueser, U., Schmidt, O.I., Oberholzer, A., Bührer, C., Stahel, P.F., IL-18: a key player in neuroinflammation and neurodegeneration?. Trends Neurosci. 28 (2005), 487–493.
15. Grande, I., Magalhaes, P.V., Kunz, M., Vieta, E., Kapczinski, F., Mediators of allostasis and systemic toxicity in bipolar disorder. Physiol. Behav. 106 (2012), 46–50.
16. Gardner, A., Boles, R.G., Beyond the serotonin hypothesis: mitochondria, inflammation and neurodegeneration in major depression and affective spectrum disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 35 (2011), 730–743.
17. Goldstein, B.I., Kemp, D.E., Soczynska, J.K., McIntyre, R.S., Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J. Clin. Psychiatry 70 (2009), 1078–1090.
18. Hamilton, M., Development of a rating scale for primary depressive illness. Br. J. Soc. Clin. Psychol. 6 (1967), 278–296.
19. Hope, S., Dieset, I., Agartz, I., Steen, N.E., Ueland, T., Melle, I., et al. Affective symptoms are associated with markers of inflammation and immune activation in bipolar disorders but not in schizophrenia. J. Psychiatry Res. 45 (2011), 1608–1616.
20. Ichiyama, T., Okada, K., Lipton, J.M., Matsubara, T., Hayashi, T., Furukawa, S., Sodium valproate inhibits production of TNF-alpha and IL-6 and activation of NF-kappaB. Brain Res. 857 (2000), 246–251.
21. Kapczinski, F., Dias, V.V., Kauer-Sant'Anna, M., Frey, B.N., Grassi-Oliveira, R., Colom, F., et al. Clinical implications of a staging model for bipolar disorders. Expert Rev. Neurother. 9 (2009), 957–966.
22. Kauer-Sant'anna, M., Kapczinski, F., Andreazza, A.C., Bond, D.J., Lam, R.W., Young, L.T., et al. Brain-derived neuro-trophic factor and inflammatory markers in patients with early-vs. late-stage bipolar disorder. Int. J. Neuropsychopharmacol. 12 (2009), 447–458.
23. Kim, Y.K., Jung, H.G., Myint, A.M., Kim, H., Park, S.H., Imbalance between pro- inflammatory and anti-inflammatory cytokines in bipolar disorder. J. Affect. Disord. 104 (2007), 91–95.
24. Knijff, E.M., Breunis, M.N., Kupka, R.W., de Wit, H.J., Ruwhof, C., Akkerhuis, G.W., et al. An imbalance in the production of IL-1beta and IL-6 by monocytes of bipolar patients: restoration by lithium treatment. Bipolar Disord. 9 (2007), 743–753.
25. Leonard, B.E., The immune system, depression and the action of antidepressants. Prog. Neuropsychopharmacol. Biol. Psychiatry 25 (2001), 767–780.
26. Luo, Y.Y., He, H.B., Zhang, M.L., Huang, X., Zhang, J., et al. Serum levels of TNF-α, IL-6 and IL-18 elevated in chronic schizophrenic patients. Schizophr. Res. 159 (2014), 556–557.
27. Merikangas, K.R., Jin, R., He, J.P., Kessler, R.C., Lee, S., Sampson, N.A., et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch. Gen. Psychiatry 68 (2011), 241–251.
28. Modabbernia, A., Taslimi, S., Brietzke, E., Ashrafi, M., Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies. Biol. Psychiatry 74 (2013), 15–25.
29. Munkholm, K., Weikpo, P., Kessing, L.V., Vinberg, M., Elevated levels of IL-6 and IL-18 in manic and hypomanic states in rapid cycling bipolar disorder patients. Brain Behav. Immun. 43 (2015), 205–213.
30. O'Brien, S.M., Scully, P., Scott, L.V., Dinan, T.G., Cytokine profiles in bipolar disorder: focus on acutely ill patients. J. Affect. Disord. 90 (2006), 263–267.
31. Ortíz-Domingues, A., Hernández, M.E., Berlanga, C., Gutiérrez-Mora, D., Moreno, J., Heinz, e G., et al. Immune variations in bipolar disorder: phasic differences. Bipolar Disord. 9 (2007), 596–602.
32. Padmos, R.C., Hillegers, M.H., Knijff, E.M., Vonk, R., Bouvy, A., Staal, F.J., et al. A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes. Arch. Gen. Psychiatry 65 (2008), 395–407.
33. Palladino, I., Salani, F., Ciaramella, A., Rubino, I.A., Caltagirone, C., Fagioli, S., et al. Elevated levels of circulating IL-18BP and perturbed regulation of IL-18 in schizophrenia. J. Neuroinflamm., 9, 2012, 206.
34. Pan, W., Kastin, A.J., Penetration of neurotrophins and cytokines across the blood-brain/ blood-spinal cord barrier. Adv. Drug Deliv. Rev. 36 (1999), 291–298.
35. Prossin, A.R., Koch, A.E., Campbell, P.L., McInnis, M.G., Zalcman, S.S., Zubieta, J.K., Association of plasma interleukin-18 levels with emotion regulation and mu-opioid neurotransmitter function in major depression and healthy volunteers. Biol. Psychiatry 69 (2011), 808–812.
36. Reale, M., Patruno, A., De Lutiis, M.A., Pesce, M., Felaco, M., Di Giannantonio, M., et al. Dysregulation of chemo-cytokine production in schizophrenic patients versus healthy controls. BMC Neurosci. 25 (2011), 12–13.
37. Rajkowska, G., Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biol. Psychiatry 48 (2000), 7667–7677.
38. Schroeter, M.L., Steiner, J., Mueller, K., Glial pathology is modified by age in mood disorderse a systematic meta-analysis of serum S100B in vivo studies. J. Affect. Disord. 134 (2011), 32–38.
39. Smith, R.S., Maes, M., The macrophage-T-lymphocyte theory of schizophrenia: additional evidence. Med. Hypotheses 45 (1995), 135–141.
40. Tanaka, K.F., Shintani, F., Fujii, Y., et al. Serum interleukin-18 levels are elevated in schizophrenia. Psychiatry Resid. 96 (2000), 75–80.
41. Watanabe, Y., Someya, T., Nawa, H., Cytokine hypothesis of schizophrenia pathogenesis: evidence from human studies and animal models. Psychiatry Clin. Neurosci. 64 (2010), 217–230.
42. Xiu, M.H., Chen, D.C., Wang, D., et al. Elevated interleukin-18 serum levels in chronic schizophrenia: association with psychopathology. J. Psychiatr. Res. 46 (2012), 1093–1098.
43. Young, R.C., Biggs, J.T., Ziegler, V.E., Meyer, D.A., A rating scale for mania: reliability, validity and sensitivity. Br. J. Psychiatry 133 (1978), 429–435.
44. Zhang, X.Y., Zhou, D.F., Cao, L.Y., Zhang, P.Y., Wu, G.Y., Shen, Y.C., Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. J. Clin. Psychiatry 65 (2004), 940–947.